Loading…

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

Saved in:

Bibliographic Details
Published in:	Leukemia 2019-01, Vol.33 (1), p.258-261
Main Authors:	Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Schlenzka, Jana, Salwender, Hans J., Munder, Markus, Gerecke, Christian, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Hillengass, Jens, Raab, Marc S., Merz, Maximilian, Baertsch, Marc-Andrea, Jauch, Anna, Hose, Dirk, Martin, Hans, Lindemann, Hans-Walter, Blau, Igor W., Scheid, Christof, Weisel, Katja C., Goldschmidt, Hartmut
Format:	Article
Language:	English
Subjects:	692/308/2779/109/1942 692/499 692/699/1541/1990/804 Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bortezomib Bortezomib - administration & dosage Brief Communication Cancer Research Critical Care Medicine Dexamethasone Dexamethasone - administration & dosage Female Follow-Up Studies Hematology Humans Induction therapy Inhibitor drugs Intensive Internal Medicine Male Medicine Medicine & Public Health Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Oncology Prognosis Remission Induction Retrospective Studies Steroids Survival Rate Targeted cancer therapy
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!